International Society for Cell & Gene Therapy (ISCT) 2026
The 2026 Meeting of the International Society for Cell and Gene Therapy (ISCT) brought together leaders from across the global CGT community at a time widely recognized as a defining period for the field. Rapid scientific progress, increasing clinical success, and continued commercialization have accelerated the pace at which therapies are reaching patients. At the same time, attention has continued to shift upstream, where early decisions around supply chain design and cellular starting materials are increasingly shaping long-term outcomes.
During this year’s meeting the IntegriCell® team from Cryoport Systems actively engaged in these conversations, contributing practical insight into the operational realities underlying scalable cell therapy manufacturing. Through multiple presentations and discussions, the team shared data-driven perspective on cryopreservation, process standardization, and the role of automation in improving consistency across the supply chain.
IntegriCell, Cryoport Systems’ integrated cryopreservation platform, is a purpose-built approach to supporting early-stage decisions that carry forward into clinical and commercial success. Engagements throughout ISCT reinforced the importance of embedding robustness and scalability upstream, as the industry continues to transition from innovation-led progress to execution-driven growth.
Poster Presentations from ISCT 2026
Poster Presentation
Ensuring Robustness and Scalability of Automated Cryopreservation for Leukapheresis Material to Support CGT Supply Chain
Automation and integrated analytics are increasingly essential to scalable and resilient cell and gene therapy (CGT) supply chains, where variability in starting material and manual, site-specific processes can compromise consistency, compliance and global deployability. The IntegriCell© Automated Closed Process (ACP) for cryopreservation was designed to standardize leukapheresis handling and leverage process data across sites.
Poster Presentation
Comparative Evaluation of Automated and Conventional Flow Cytometry Methods for Leukapheresis Characterization Upon Cryopreservation Process
Cryopreservation has opened the door to flexible, decentralized workflows, but lacks standardized methods for robust sample characterization. This poster compares performance of flow cytometry and automated platforms using cryopreserved leukapheresis. Combining these two automated processes simplifies and accelerates tech transfers and increases operational consistency under GMP-relevant conditions.
Poster Presentation
Robust Automated Leukapheresis Cryo-processing Enables High-quality Material for Both Autologous and Allogenic CAR T-cell Therapy Manufacturing
Due to the logistical challenges, selecting the appropriate starting material for apheresis, whether fresh or frozen, is crucial in cell therapy. Understanding these differences is vital for optimizing the manufacturing process and ensuring the highest quality and efficacy of CAR T-cell products. This poster explores how our Automated Closed Cryopreservation Process (ACP) preserves cell viability and phenotype post-thawing.
Thank you to those who engaged with us during ISCT 2026 in Dublin.
Our onsite team spanned technical operations, process development, quality, and commercial leadership. Throughout the event, team members participated in oral presentations, poster sessions, and global showcase programming, contributing to the dialogue around improving quality, consistency, and scalability of cellular starting materials.
Beyond formal sessions, the team spoke with many peers across the CGT ecosystem to exchange perspectives on the evolving challenges of commercialization and global supply chain readiness. These interactions created space for more grounded, experience-driven discussions about how early operational decisions influence downstream success.
Our sincere thanks to all of our colleagues, peers, and industry professionals who participated in ISCT 2026 and who share our ongoing commitment to advancing practical solutions that support the maturation of cell and gene therapies from early development through to broader patient access.
-
Matthew Plaud
Chief Operations Officer, IntegriCell™ -
Dominic Clarke
Vice President – Technical Operations IntegriCell™ -
Alice Bouchoms
Process Development Manager -
Shawne Thorsen
Process Engineer -
Apolline Fossion
AD/QC Specialist -
Michael Iweins
Senior Manager – Technical Operations -
Romain Robert
Sr. Process Engineer MS&T -
Corentin Maghe
Manager- Quality Assurance & Regulatory Affairs
Our team participated in these events during ISCT 2026
Oral Abstract Session : Robust automated leukapheresis cryo-processing enables high-quality starting material for both autologous and allogeneic CAR-T cell therapy manufacturing
Shawne Thorsen, Process Engineer
When: Wednesday, May 6, 2026 at 11:35am – 11:45am
Location: Liffey Hall 2
Poster Presentation: Comparative evaluation of automated and conventional flow cytometry methods for characterizing leukapheresis during the cryopreservation process
Apolline Fossion, AD/QC Specialist
When: Wednesday, May 6, 2026 at 7:00pm – 8:30pm
Location: Poster #921
Poster Presentation: Ensuring robustness and scalability of automated cryopreservation for leukapheresis material to support CGT supply chains
Alice Bouchoms, Process Development Manager
When: Wednesday, May 6, 2026 at 7:00pm – 8:30pm
Location: Poster #909
Poster Presentation: Robust automated leukapheresis cryo-processing enables high-quality starting material for both autologous and allogeneic CAR-T cell therapy manufacturing
Shawne Thorsen, Process Engineer
When: Wednesday, May 6, 2026 at 7:00pm – 8:30pm
Location: Poster #18
Global Showcase Presentation: Comparative Evaluation of Automated and Conventional Flow Cytometry Methods for Leukapheresis characterization upon Cryopreservation Processes
Dominic Clarke, Vice President – Technical Operations, Integricell
When: Thursday, May 7, 2026 at 3:30pm – 3:45pm
Location: Global Showcase Theatre A
Elevator Pitch Session: Ensuring robustness and scalability of automated cryopreservation for leukapheresis material to support CGT supply chains
Alice Bouchoms, Process Development Manager
When: Thursday, May 7, 2026 at 5:00pm – 5:45pm
Location: Global Showcase Theater A
About Cryoport Systems
Cryoport Systems is a comprehensive supply chain partner for the life sciences industry focused on meeting the challenges of the global cell and gene therapy market. We excel in the specialized management of the biopharma supply chain through our comprehensive offerings in logistics, BioServices and biostorage, cryopreservation, and consulting. With our expansive platform and decades of temperature-controlled supply chain expertise, Cryoport Systems helps Enable the Outcome™ for advanced therapies programs, safely and securely guiding critical therapies to patients in need.
About the Conference
International Society for Cell & Gene Therapy Annual Meeting takes an integrative approach across all stakeholders to address key topics spanning translational research and preclinical development through to clinical trials, regulatory approvals, commercialization, and ultimately patient access.
Let’s Connect
Interested in setting up a time to talk with our team of experts? Looking to follow up on a recent presentation or booth conversation? We’d love to hear from you! Fill out the form below and our team will be in touch.